STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues
Sanofi collaboration revenue	$ 326,609	$ 311,332	$ 247,140
Other collaboration revenue	43,072	75,393	67,317
Net product sales	44,686	25,254	18,364
Technology licensing	24,858	40,150	40,013
Contract research and other	6,599	6,945	6,434
Total revenues	445,824	459,074	379,268
Expenses
Research and development	529,506	489,252	398,762
Selling, general, and admistrative	117,261	65,201	52,923
Cost of goods sold	4,216	2,093	1,686
Total expenses	650,983	556,546	453,371
Loss from operations	(205,159)	(97,472)	(74,103)
Other income (expense)
Investment income	3,549	2,122	4,488
Interest expense	(21,282)	(9,118)	(2,337)
Total other income (expense)	(17,733)	(6,996)	2,151
Net loss before income tax benefit	(222,892)	(104,468)	(71,952)
Income tax benefit	(1,132)	0	(4,122)
Net loss	$ (221,760)	$ (104,468)	$ (67,830)
Net loss per share, basic and diluted (in dollars per share)	$ (2.45)	$ (1.26)	$ (0.85)
Weighted average shares outstanding, basic and diluted (in shares)	90,610	82,926	79,782